Phase III RECOVER trial
Apr 12, 2024
Hope on the Horizon: Brilaroxazine’s Promise for Schizophrenia Patients
Brilaroxazine, developed by Reviva Therapeutics, exhibits potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia. Brilaroxazine’s pharmacological profile sets it apart from traditional antipsychotics. Operating as a partial agonist at D2/3/4 and 5-HT1A/2A recept...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
